How did Concord Drugs' profitability change in FY26?

Standalone net profit rose to ₹1.04 crore from ₹0.30 crore, driven by revenue more than doubling to ₹75.85 crore.

What is the auditor's concern about receivables?

The auditor issued an emphasis of matter noting ₹4.14 crore in trade receivables that are long overdue. This amount is nearly four times the company's full-year net profit.

Is this the first time these results have been reported?

No. The analyst rationale states these same results were already disseminated in a prior filing, so the board meeting outcome adds no new financial information.

Earnings · Pharmaceuticals · Micro cap

Concord Drugs doubles revenue, auditor flags ₹4.14 cr overdue receivables

Audited FY26 standalone revenue rose to ₹75.85 cr, but the auditor's emphasis of matter on long-overdue receivables is the real story.

— 1 earlier story on Concord Drugs Ltd. →

CONCORD By Tipsheet Editorial 27 May 2026 · 4:37 PM IST Verify on BSE · NSE

Mkt cap₹101 cr

P/E95.40×

ROE0.99%

Debt / eq.0.56

₹75.85 cr Standalone FY26 revenue, more than double the prior year's ₹36.93 cr

What's new

Board approved audited FY26 results: standalone revenue rose to ₹75.85 cr from ₹36.93 cr.
Standalone net profit jumped to ₹1.04 cr from ₹0.30 cr in the prior year.
Auditor issued an emphasis of matter on ₹4.14 cr in long-overdue trade receivables.

Why this matters

For a nano-cap, doubling revenue is a material shift in scale. But the auditor's emphasis on ₹4.14 cr in overdue receivables, a sum nearly four times the full-year net profit, casts doubt on how much of that top-line growth converted to cash. The results themselves are not new information.

What we're watching

Whether the overdue receivables are eventually written down.
If revenue growth can be sustained into FY27.
Cash flow from operations relative to the reported profit.

The full read

Concord Drugs' audited FY26 numbers show standalone revenue more than doubling to ₹75.85 crore from ₹36.93 crore, with net profit jumping to ₹1.04 crore from ₹0.30 crore. The results are not new. The more interesting disclosure is the auditor's emphasis of matter on ₹4.14 crore in long-overdue trade receivables. For a nano-cap, that sum is large and represents nearly four times the full-year net profit. Whether that cash eventually gets collected, or written off, will determine how much of the headline revenue growth translates to real value.

Questions answered

How did Concord Drugs' profitability change in FY26?: Standalone net profit rose to ₹1.04 crore from ₹0.30 crore, driven by revenue more than doubling to ₹75.85 crore.
What is the auditor's concern about receivables?: The auditor issued an emphasis of matter noting ₹4.14 crore in trade receivables that are long overdue. This amount is nearly four times the company's full-year net profit.
Is this the first time these results have been reported?: No. The analyst rationale states these same results were already disseminated in a prior filing, so the board meeting outcome adds no new financial information.

Mentioned: ₹4.14 cr overdue receivables · Standalone FY26 results

Primary source BSE · NSE · Tijori

An independent reading of the company's own disclosure — the primary filing above is the final word.

Company snapshot

Concord Drugs Ltd.

Pharmaceuticals

₹100 cr

P/E 95.01×

Latest quarter · Mar 2026

Sales₹38 cr

Net profit₹1 cr

Op. margin+4.0%

EPS₹0.40

Strength & growth

Debt / equity0.56×

Current ratio1.56×

Sales CAGR+4.3%

EPS CAGR−17.1%

Story so far

All notes on CONCORD →

27 May 2026 · 4:37 PM IST Concord Drugs doubles revenue, auditor flags ₹4.14 cr overdue receivables
49d ago Concord Drugs doubled revenue. The auditor flagged ₹4.14 cr with no provision.